Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 0.38 |
| ▸ | JAK2 | O60674 | 15/20 | 0.38 |
| ▸ | CDK2 | P24941 | 9/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.38 |
| ▸ | TYK2 | P29597 | 11/20 | 0.34 |
| ▸ | JAK1 | P23458 | 9/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258270 | 0.90 | EGFR (0.39) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL463798 | 0.90 | FLT3 (0.36) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL414918 | 0.86 | JAK2 (0.36) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL10258592 | 0.79 | EGFR (0.38) | FLT3EGFRTP53AXLTYRO3 | |
| SCHEMBL463810 | 0.79 | EGFR (0.36) | FLT3EGFRAXLTYRO3MERTK | |
| SCHEMBL414378 | 0.77 | EGFR (0.39) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL415909 | 0.76 | EGFR (0.38) | EGFRTP53 | |
| SCHEMBL10258378 | 0.76 | EGFR (0.37) | EGFRTP53 | |
| SCHEMBL463767 | 0.75 | EGFR (0.38) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL413802 | 0.74 | EGFR (0.36) | FLT3JAK2CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | FLT3 2149/4885JAK2 2835/4885CDK2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.